SCHEMBL20052615

SCHEMBL20052615

CON(C)C(=O)C(=O)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
FABP7 O15540 2/20 0.45
FABP5 Q01469 2/20 0.45
LMNA P02545 2/20 0.45
APP P05067 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
MEN1 O00255 1/20 0.43
ABCB1 P08183 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
HTT P42858 1/20 0.42
CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23027283 0.84 ALDH1A1 (0.58) ALDH1A1MAPTHPGDKMT2ATDP1
Trimethylammonium SCHEMBL7965217 0.79 ALDH1A1 (0.60) ALDH1A1MAPTHPGDKMT2ATDP1
SCHEMBL22566998 0.79 ALDH1A1 (0.51) ALDH1A1MAPTHPGDKMT2ATDP1
SCHEMBL24843177 0.79 ALDH1A1 (0.51) ALDH1A1MAPTHPGDKMT2ATDP1
SCHEMBL27144 0.78 ALDH1A1 (0.68) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL5145651 0.77 ALDH1A1 (0.62) ALDH1A1MAPTHPGDKMT2ATDP1
SCHEMBL24758600 0.76 ALDH1A1 (0.49) ALDH1A1MAPTHPGDKMT2ATDP1
SCHEMBL20173277 0.76 ALDH1A1 (0.49) ALDH1A1MAPTHPGDKMT2ATDP1
SCHEMBL4623851 0.76 ALDH1A1 (0.56) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
Ammonia Solution, Strong SCHEMBL27884853 0.75 ALDH1A1 (0.60) ALDH1A1MAPTHPGDKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002392-A1 Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors INCYTE CORPORATION 2023-01-05 US disclosed
US-10738052-B2 Imidazotriaines and imidazopyrimidines as kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2020-08-11 US disclosed
US-9944645-B2 Imidazotriazines and imidazopyrimidines as kinase inhibitors INCYTE CORPORATION (US) 2018-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002392-A1 Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors ERBB2, MERTK, ABL1 ALDH1A1 1368/4885MAPT 2706/4885HPGD 4588/4885
US-10738052-B2 Imidazotriaines and imidazopyrimidines as kinase inhibitors MET, RET, ERBB2 ALDH1A1 1246/4885MAPT 2424/4885HPGD 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.